Understanding the Growth Hormone Therapy Adherence Paradigm: A Systematic Review

被引:120
作者
Fisher, Benjamin G. [1 ]
Acerini, Carlo L. [1 ,2 ]
机构
[1] Univ Cambridge, Dept Paediat, Cambridge CB2 0QQ, England
[2] Cambridge Univ Hosp Fdn NHS Trust, Weston Ctr, Inst Metab Sci, Cambridge CB2 0QQ, England
来源
HORMONE RESEARCH IN PAEDIATRICS | 2013年 / 79卷 / 04期
关键词
Growth hormone therapy; Serum insulin-like growth factor I; Patient compliance; GH-DEFICIENT ADULTS; QUALITY-OF-LIFE; I IGF-I; PATIENT ADHERENCE; CROSSOVER TRIAL; TURNER-SYNDROME; RENAL-FAILURE; SHORT-STATURE; CHILDREN; INJECTION;
D O I
10.1159/000350251
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Growth hormone (GH) therapy is used to treat a variety of growth disorders in childhood/adolescence. Its efficacy is thought to be dependent on patients' adherence to their treatment regimen. Methods: PubMed was searched using the keywords 'growth hormone', 'child'[Mesh], 'adolescent'[Mesh], and 'patient compliance'[Mesh]. Results: Most studies of adherence to paediatric GH therapy have used either issued/encashed GH prescriptions or questionnaires. Estimates of prevalence of non-adherence vary from 5-82%, depending on the methods and definitions used. Different studies have variously demonstrated an association (or lack thereof) between adherence and age, socioeconomic status, treatment duration, injection device used and injection-giver. A number of interventions have been proposed to improve adherence, including offering a choice of injection device, but none are supported by trials. Poor adherence is associated with reduced height velocity and likely increased economic costs; evidence for other effects is circumstantial. Conclusion: Adherence to paediatric GH therapy is suboptimal, which may partially explain why the mean final height attained is below that of the general population. Analysis of the causes of non-adherence is complicated by conflicting evidence from different studies. Multifactorial interventions are most likely to be successful in improving adherence. We make recommendations for further research. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码:189 / 196
页数:8
相关论文
共 77 条
  • [31] Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990
  • [32] Long-Acting Growth Hormone for Replacement Therapy
    Johannsson, Gudmundur
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) : 1668 - 1670
  • [33] Growth hormone (GH) replacement in GH-deficient adults:: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections
    Johansson, JO
    Wirén, L
    Oscarsson, J
    Bengtsson, BÅ
    Johannsson, G
    [J]. GROWTH HORMONE & IGF RESEARCH, 2003, 13 (06) : 306 - 315
  • [34] JORGENSEN JT, 1994, J PEDIATR ENDOCRINOL, V7, P175
  • [35] Monitoring of concordance in growth hormone therapy
    Kapoor, R. R.
    Burke, S. A.
    Sparrow, S. E.
    Hughes, I. A.
    Dunger, D. B.
    Ong, K. K.
    Acerini, C. L.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2008, 93 (02) : 147 - 148
  • [36] Indications for growth hormone therapy in children
    Kirk, Jeremy
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2012, 97 (01) : 63 - 68
  • [37] Support as a crucial predictor of good compliance of adolescents with a chronic disease
    Kyngäs, H
    Rissanen, M
    [J]. JOURNAL OF CLINICAL NURSING, 2001, 10 (06) : 767 - 774
  • [38] Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?
    Lanes, R
    Jakubowicz, S
    [J]. JOURNAL OF PEDIATRICS, 2002, 141 (05) : 606 - 610
  • [39] National Audit of Patient Choice in Pediatric GH Therapy
    Langham, Shirley
    Kirk, Jeremy
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2011, 75 (02): : 101 - 105
  • [40] Individualizing growth hormone dosing in children
    Lee, KW
    Cohen, P
    [J]. HORMONE RESEARCH, 2001, 56 : 29 - 34